Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERIANNA vs EUTHYROX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Hypothyroidism (primary, secondary, tertiary),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Thyroid hormone replacement therapy in myxedema coma,Off-label: Subclinical hypothyroidism (when TSH >10 m IU/L or with symptoms)
2.5 mg orally once daily
Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
Terminal half-life: 6-7 days in euthyroid individuals. Longer in hypothyroidism (9-10 days) and shorter in hyperthyroidism (3-4 days). Clinically, steady-state achieved in 4-6 weeks.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Partially deiodinated to active T3 and inactive reverse T3 (r T3) in liver, kidney, and other tissues. Conjugation with glucuronides and sulfates. Minimal CYP450 involvement.
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
Primarily renal (approximately 40-50% as unchanged drug and metabolites), with about 20% fecal elimination via bile. Minor biliary excretion.
95% bound primarily to albumin and alpha-1-acid glycoprotein.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Lewothyroxine is the active form.
0.5-0.7 L/kg, indicating moderate tissue distribution.
0.10-0.15 L/kg, reflecting distribution primarily into extracellular fluid and tissues with high affinity binding to thyroid hormone receptors.
Oral bioavailability: 60-80%.
Oral: 50-80% (variable, influenced by food, GI disease, and formulation). IV: 100%.
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No renal adjustment required as levothyroxine is primarily metabolized and excreted in feces. Monitor TSH and free T4 in patients with severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
No specific Child-Pugh adjustment; however, severe hepatic impairment may reduce T4 to T3 conversion; monitor thyroid function tests.
Not approved for pediatric use
Weight-based: 0-3 months: 10-15 mcg/kg/day; 3-6 months: 8-10 mcg/kg/day; 6-12 months: 6-8 mcg/kg/day; 1-5 years: 5-6 mcg/kg/day; 6-12 years: 4-5 mcg/kg/day; >12 years: 2-3 mcg/kg/day. Administer orally once daily.
No specific dose adjustment; monitor renal function due to age-related decline
Elderly patients (especially >65 years) or those with cardiovascular disease: start at 12.5-25 mcg orally once daily; increase by 12.5 mcg every 4-6 weeks; lower maintenance doses often required.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
Not approved for weight loss. Doses above physiologic requirements may produce serious or life-threatening toxicity, especially when used with sympathomimetic amines.
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Cardiovascular effects (angina, arrhythmias, hypertension) in patients with underlying heart disease. Risk of thyrotoxic crisis if dose is excessive. Adrenal insufficiency: adjust corticosteroid dose before starting in patients with adrenal insufficiency. Diabetes mellitus: may increase blood glucose and require adjustment of antidiabetic therapy. Osteoporosis: chronic TSH suppression increases risk of bone loss. Interactions with anticoagulants (warfarin), antidiabetic agents, and SSRIs. Discontinue use for weight loss due to serious toxicity.
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Levothyroxine absorption is decreased by high-fiber foods (e.g., bran, whole grains), soy products, grapefruit juice, walnuts, and cottonseed meal. Also, calcium-fortified foods and beverages can reduce absorption. Take levothyroxine at least 4 hours apart from these foods. Avoid concomitant ingestion with coffee or milk; if needed, maintain consistency. Caffeine may slightly reduce absorption.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm birth, and low birth weight. The drug does not cross the placenta significantly; fetal thyroid function is independent. No known teratogenic effects from levothyroxine at therapeutic doses. First trimester: essential for maternal euthyroidism to prevent fetal neurodevelopmental impairment. Second and third trimesters: maintenance of maternal euthyroidism supports normal fetal growth and development. Insufficient treatment increases risks.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Levothyroxine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is generally considered compatible with breastfeeding at therapeutic doses as it does not pose a risk to the infant. Monitoring infant thyroid function is not routinely required unless maternal dose is very high or infant shows symptoms.
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
Pregnancy increases thyroid-binding globulin and plasma volume, leading to increased levothyroxine requirements. Dose often increases by 30-50% during pregnancy, starting as early as 4-6 weeks gestation. Frequent monitoring (every 4 weeks) and dose adjustments are necessary to maintain TSH in trimester-specific ranges: first trimester 0.1-2.5 m IU/L, second trimester 0.2-3.0 m IU/L, third trimester 0.3-3.0 m IU/L. Postpartum dose should be reduced to pre-pregnancy levels.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Levothyroxine (EUTHYROX) is the standard therapy for hypothyroidism. Absorption is reduced by calcium, iron, soy, and fiber; take on an empty stomach 30-60 minutes before breakfast. Dose adjustments needed in pregnancy, weight changes, and with interacting drugs (e.g., estrogens, rifampin, phenytoin). Monitor TSH 6-8 weeks after dose change. In hyperthyroidism, rapid levothyroxine withdrawal can precipitate thyroid storm; taper cautiously. For myxedema coma, use IV levothyroxine (not oral). When switching from a T3-containing preparation, cross-titration is required.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
Take levothyroxine exactly as prescribed, at the same time each day.,Take on an empty stomach, at least 30-60 minutes before breakfast or any food.,Do not take with calcium supplements, iron supplements, antacids, or high-fiber foods; separate by at least 4 hours.,Do not stop or change dose without consulting your doctor.,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose; do not double dose.,Report symptoms of hyperthyroidism (rapid heart rate, palpitations, anxiety, weight loss) or hypothyroidism (fatigue, weight gain, cold intolerance).,Blood tests (TSH) will be done regularly to monitor dose.,Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Keep all medications out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERIANNA vs EUTHYROX, answered by our medical review team.
CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. EUTHYROX is a Thyroid Hormone Replacement that works by Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERIANNA and EUTHYROX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERIANNA is: 2.5 mg orally once daily. The standard adult dose of EUTHYROX is: Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERIANNA and EUTHYROX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. EUTHYROX is classified as Category C. EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm bir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.